Market Data 
Markets
Replies to post #765777 on NorthWest Biotherapeutics Inc (NWBO)
Would somebody please notice that the 10K is the status of events as of December 31 2024.
On February 14, 2025, both Plaintiffs and Defendants filed their respective comments on this latest R&R from the Magistrate Judge and on February 28, 2025, each party filed comments on the other parties February 14, 2025 filings. On March 5, 2025, defendants once again filed a motion seeking an oral argument on the most recent issues raised in the Magistrate Judge’s R&R, and on March 6, 2025, Senior Judge Woods denied the motion in writing without prejudice.
On March 26, 2025, Senior Judge Woods issued his opinion adopting Magistrate Stein’s R&R. The next step will be a status conference with the Court to set the discovery schedule for the case.
As of March 28, 2025, there were approximately 46,428 holders of record of our common stock.
Potential Manufacturing in the US. During much of 2024 and Q1 2025, the Company has been in discussions with a series of half a dozen independent parties with GMP facilities in diverse areas of the US, to obtain capacity and availability for potential manufacturing in the US. The manufacturing is initially contemplated to include DCVax-L products and DC products involving the IP in-licensed from Roswell Park and the University of Pittsburgh.
AI
